A randomised double blind trial was conducted to determine the efficacy of inhaled bronchodilators, salbutamol and ipratropium bromide, compared with placebo in the treatment of bronchiolitis. Patients, who were 2 months to 2 years of age and without underlying cardiac or pulmonary disease, received drug 1 (salbutamol or saline placebo) followed one hour later by drug 2 (ipratropium bromide or ...

We have investigated possible mechanisms of response to airway cooling by studying the effects of sodium cromoglycate and ipratropium bromide on the changes in airways resistance that followed eucapnic hyperventilation with subfreezing air in a group of 12 patients with mild asthma and 10 normal subjects. We have also studied the period of refractoriness to repeated challenge. Maximum bronchoco...

1. Forced expiratory flow rates and specific airways conductance were measured before and after the inhalation of the atropine-like drug ipratropium bromide in 11 diabetic patients with autonomic neuropathy and a control group of 11 diabetic patients without autonomic neuropathy. Respiratory muscle function was assessed by recording maximal inspiratory and expiratory mouth pressures. 2. There w...

Objective: Evaluate the effectiveness of Ipratropium Bromide in combination with Salbutamol and alone for treatment recurrent wheezes children asthma who seek care at LRH, Peshawar. Methods: After approval from institution review board, this randomized controlled trial was performed Department Pediatrics, Peshawar, 7th January 2021 to July 2021. A total 128 patients met inclusion criteria were ...

The bronchodilator activity in nebulised salbutamol, ipratropium bromide, clemastine, and a placebo was studied in 14 asthmatic children aged between 3 and 5 years. Changes in lung function were monitored by measuring peak expiratory flow rate and total respiratory resistance using a modification of the forced oscillation technique. Ipratropium bromide produced a degree of bronchodilation simil...

BACKGROUND There is uncertainty regarding the use of monotherapy or combination therapy with beta 2 agonists and anticholinergic drugs in patients with chronic obstructive pulmonary disease (COPD). The measurement of forced expiratory volume in one second (FEV1) or relaxed vital capacity (RVC) in the assessment of reversibility in these patients has also caused considerable debate. METHODS Tw...

In obstructive lung disease, inhaled ipratropium and oxitropium gives a bronchodilation. When tested in patients in "stable" condition the maximum effect is seen from 40 mg ipratropium. In allergic bronchial asthma, the bronchodilation from inhaled anticholinergic drugs seem inferior to the effect from an inhaled beta-agonist but in older, non-atopic patients the bronchodilations from an antich...

Inhaled tiotropium provides a sustained bronchodilator effect over a 24-hour period in patients with chronic obstructive pulmonary disease (COPD). There is some evidence that tiotropium 18 micro g once daily is more efficacious than ipratropium bromide 40 micro g four times daily, for patients with COPD, as measured by improvements in lung function, dyspnea disease-specific quality of life and ...

BACKGROUND There is concern about an increase in deaths from respiratory causes in asthma patients using long acting beta agonists. According to the guidelines of the British Thoracic Society, long acting beta agonists, ipratropium bromide, and theophylline should be used to treat patients with increasing asthma severity who are already receiving treatment with short acting beta agonists and in...

Tiotropium, a novel once-daily inhaled anticholinergic, has been shown to improve lung function over a 24-h period. In order to extend these findings, health-outcomes were evaluated over 1 yr in chronic obstructive pulmonary disease (COPD) patients. Spirometric results, peak expiratory flow rate (PEFR), salbutamol use and effects on dyspnoea, health-related quality of life and COPD exacerbation...